

Microsoft Bing

国内版 国际版

Therapeutic Resistance in PDAC: Current Challenges and Future Op

Sign in

Add the Give with Bing extension

ALL IMAGES VIDEOS

2,040,000 Results Any time

</

548,000 Results

Any time ▾

## Pancreatic Cancer: Current Progress and Future Challenges ...

[europepmc.org/articles/PMC4753155](https://europepmc.org/articles/PMC4753155)

Therapeutic resistance is one of the major challenges in improving disease outcome in **pancreatic cancer**. Chand and colleagues discussed the potential mechanisms of **therapeutic resistance** in their article entitled "The landscape of **pancreatic cancer therapeutic resistance** mechanisms" 7 and highlighted the potential targets to overcome the highly stubborn resistance and enhance drug efficacy in **pancreatic cancer**.

Cited by: 20

Author: S. Pervez Hussain

Publish Year: 2016

## Pancreatic Cancer: Current Progress and Future Challenges

<https://www.ijbs.com/v12p0270.htm> ▾

Feb 03, 2016 · Therapeutic resistance is one of the major challenges in improving disease outcome in **pancreatic cancer**. Chand and colleagues discussed the potential mechanisms of **therapeutic resistance** in their article entitled "The landscape of **pancreatic cancer therapeutic resistance** mechanisms" ( 7 ) and highlighted the potential targets to overcome the highly stubborn resistance and enhance drug efficacy in **pancreatic cancer**.

## [PDF] Pancreatic Cancer: Current Progress and Future Challenges

[www.ijbs.com/v12p0270.pdf](http://www.ijbs.com/v12p0270.pdf)

lection of articles key issues have been discussed to understand, combat and ultimately defeat this lethal malignancy with focus on the **current** progress and **future challenges** to improve early detection and treatment strategies. **Therapeutic resistance** is one of the major chal-lenges in improving disease

**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 65602

**Manuscript Type:** REVIEW

#### **Therapeutic Resistance in PDAC: Current Challenges and Future Opportunities**

PDAC: Current therapies and future opportunities

#### **Abstract**

Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related deaths in the USA. Although chemotherapeutic regimens such as gemcitabine+ nab-paclitaxel and FOLFIRINOX significantly improve patient survival, the prevalence of therapy resistance remains a major roadblock in the success of these agents. This review discusses the molecular mechanisms that play a crucial role in PDAC therapy resistance and how a better understanding of these mechanisms has shaped clinical trials for pancreatic cancer chemotherapy. Specifically, we have discussed the metabolic

#### **Match Overview**

1	Internet 29 words crawled on 28-Jun-2020 <a href="http://www.nature.com">www.nature.com</a>	1%
2	Crossref 27 words Lukas Fleckholder, Johanne Gout, Elodie Roger, Fernando Ku de Almeida et al. "DNA damage repair as a target in pe ...	<1%
3	Internet 27 words crawled on 18-Jul-2021 <a href="http://www.frontiersin.org">www.frontiersin.org</a>	<1%
4	Internet 17 words crawled on 07-Nov-2020 <a href="http://cancerandmetabolism.biomedcentral.com">cancerandmetabolism.biomedcentral.com</a>	<1%
5	Internet 17 words crawled on 20-Jul-2020 <a href="http://www.oncotarget.com">www.oncotarget.com</a>	<1%
6	Internet 16 words crawled on 25-Mar-2021 <a href="http://www.abcam.com">www.abcam.com</a>	<1%
7	Internet 15 words crawled on 12-Sep-2020 <a href="http://ro-journal.biomedcentral.com">ro-journal.biomedcentral.com</a>	<1%
8	Internet 15 words crawled on 29-Mar-2020 <a href="http://www.science.gov">www.science.gov</a>	<1%

国内版

国际版

Therapeutic resistance in pancreatic ductal adenocarcinoma: Curre



ALL

IMAGES

VIDEOS

102,000 Results

Any time ▾

### [Gemcitabine resistance in pancreatic ductal adenocarcinoma](#)

<https://pubmed.ncbi.nlm.nih.gov/26690340>

Pancreatic ductal adenocarcinoma (PDA) ranks fourth among cancer related deaths. The disappointing 5-year survival rate of below 5% stems from drug **resistance** to all known therapies, as well as from disease presentation at a late stage when PDA is already metastatic. Gemcitabine has been the corners ...

Cited by: 170

Author: Yoav Binenbaum, Shorook Na'ara, Ziv Gil

Publish Year: 2015

### [Pancreatic Ductal Adenocarcinoma: Biological Hallmarks ...](#)

<https://pubmed.ncbi.nlm.nih.gov/31395068>

Pancreatic ductal adenocarcinoma (PDAC) is a highly devastating disease with poor prognosis and rising incidence. Late detection and a particularly aggressive biology are the major **challenges** which determine **therapeutic** failure. In this review, we present the **current** status and the recent advances i ...

Cited by: 117

Author: Michael Orth, Michael Orth, Philipp Metz...

Publish Year: 2019

### [Epigenetic Landscape in Pancreatic Ductal Adenocarcinoma ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311973>

Jun 08, 2020 · Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive solid malignancies due to the rapid rate of metastasis and high **resistance** to currently applied cancer therapies. The complex mechanism underlying the development and progression of PDAC includes interactions between genomic, epigenomic, and signaling pathway alterations.

Cited by: 4

Author: Sona Ciernikova, Julie Earl, Maria Laura ...

Publish Year: 2020

### [Therapeutic developments in pancreatic cancer: current and ...](#)

<https://www.nature.com/articles/s41575-018-0005-x>

May 01, 2018 · The overall 5-year survival for pancreatic cancer has changed little over the past few decades, and **pancreatic** cancer is predicted to be the second ...

Cited by: 354

Author: John P. Neoptolemos, Jörg Kleeff, Jörg Kl...

Publish Year: 2018